Article
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
Annals of oncology : official journal of the European Society for Medical Oncology - 1 May 2016
Drilon A, Li G, Dogan S, Gounder M, Shen R, Arcila M, Wang L, Hyman D M, Hechtman J, Wei G, Cam N R, Christiansen J, Luo D, Maneval E C, Bauer T, Patel M, Liu S V, Ou S H I, Farago A, Shaw A, Shoemaker R F, Lim J, Hornby Z, Multani P, Ladanyi M, Berger M, Katabi N, Ghossein R, Ho A L
Abstract excerpt
BACKGROUND: Mammary analogue secretory carcinoma (MASC) is a recently described pathologic entity. We report the case of a patient with an initial diagnosis of salivary acinic cell carcinoma later reclassified as MASC after next-generation sequencing revealed an ETV6-NTRK3 fusion. PATIENTS AND METHODS: This alteration was targeted with the pan-Trk inhibitor entrectinib (Ignyta), which possesses potent in vitro...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.